Stock Selection: Grok 4.7's picks for 2026-10-30
Grok 4.7 picked REGN, CDNA, LLY, XOM, MDLZ for a 1-day horizon. Portfolio return vs SPY: -0.38%. Picks that beat SPY: 40%.
| Experiment | Stock Selection |
|---|---|
| Model | Grok 4.7 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-30 |
| Measured to | 2026-11-02 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -0.38% |
| Picks that beat SPY | 40% |
| Benchmark return | +0.31% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | REGN | +5.68% | 82% | +5.37% | Yes |
| 2 | CDNA | -5.45% | 78% | -5.76% | No |
| 3 | LLY | -1.57% | 75% | -1.88% | No |
| 4 | XOM | -1.35% | 72% | -1.66% | No |
| 5 | MDLZ | +2.32% | 70% | +2.01% | Yes |
The model's market view
US markets are in a risk-off session driven by disappointing Amazon and Intel earnings that intensified concerns over heavy AI capital spending and cash flow. The Nasdaq is down roughly 2% and SPY is lower by about 1.2%, while defensive sectors including healthcare and consumer staples, plus energy supported by higher oil prices from Middle East tensions, are outperforming.
Why each pick
REGN
Regeneron surged after a strong Q3 beat, with EPS of $20.07 versus estimates around $16.25 and robust Dupixent-related profits, sending shares up more than 11% intraday to a multi-year high. Thesis: continued positive reaction and relative strength versus the tech-led selloff should allow it to outperform SPY over the next session. Risks: profit-taking after the large gap higher, or broader market weakness dragging even defensives lower. Latest intraday quote used.
CDNA
CareDx jumped over 20% on a Q3 earnings and revenue beat, guidance raise, and analyst price-target increases, reflecting strong transplant-testing growth. Thesis: high-momentum earnings winner with elevated volume is likely to sustain relative outperformance against a declining SPY. Risks: sharp reversal if profit-taking hits small-cap biotech names, or if broader risk-off intensifies. Latest intraday quote used.
LLY
Eli Lilly is higher after raising its 2026 sales outlook on strong obesity and diabetes drug demand (tirzepatide franchise). Thesis: secular growth in GLP-1s and defensive healthcare rotation should support outperformance versus SPY in the current tech-pressure environment. Risks: valuation remains elevated and any macro growth scare could pressure high-multiple names. Latest intraday quote used.
XOM
ExxonMobil is advancing after topping Q3 estimates on stronger refining margins and as crude oil rises on Middle East supply concerns. Thesis: energy sector strength and positive earnings reaction provide a hedge and relative upside versus a tech-heavy SPY decline. Risks: oil-price pullback or broader equity weakness could limit gains. Latest intraday quote used.
MDLZ
Mondelez is up after a Q3 earnings beat driven by cost controls and volume gains, with management reaffirming guidance. Thesis: consumer-staples defensive characteristics and positive earnings reaction support relative outperformance in a risk-off session. Risks: modest absolute upside potential and possible fade if the market rebounds into growth names. Latest intraday quote used.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Perplexity | XOM, CVX, LLY, MRK, XLE | -1.43% | 0% |
| Muse Spark 1.1 | REGN, XOM, CVX, MDLZ, CDNA | -0.36% | 40% |
| Claude Opus 5.5 | REGN, XLV, MDLZ, XOM, CL | +1.04% | 60% |
| DeepSeek | XOM, XLE, LLY, XLP, XLV | -1.20% | 20% |
| Gemini 3 Pro | LLY, XLV, WMT, XLE, MRK | -0.66% | 20% |
| GPT-6 | XLP, SNY, XOM, RSP, BTSG | -0.30% | 60% |
Written up on ForecastNest Insights: Stock Selection: Grok 4.7's picks for 2026-10-30.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.